http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Juan Zhou,San-Gang Wu,Jun-Jie Wang,Jia-Yuan Sun,Fengyan Li,Qin Lin,Huan-Xin Lin,Zhen-Yu He 대한암학회 2015 Cancer Research and Treatment Vol.47 No.1
Purpose The purpose of this study was to assess the value of ovarian ablation using goserelin inpremenopausal patients with stage II/III hormone receptor-positive breast cancer withoutchemotherapy-induced amenorrhea (CIA). Materials and MethodsWe retrospectively reviewed the data of breast patients treated between October 1999 andNovember 2007 without CIA. The Kaplan-Meier method was used for calculation of thesurvival rate. Log rank method and Cox regression analysis were used for univariate andmultivariate prognostic analysis. ResultsThe median follow-up period was 61 months. Initially, 353 patients remained without CIAafter chemotherapy and 98 among those who received goserelin and tamoxifen (TAM). Inunivariate analysis, goserelin improved locoregional recurrence-free survival (LRFS) (98.9%vs. 94.1%, p=0.041), distant metastasis-free survival (DMFS) (85.4% vs. 71.9%, p=0.006),disease-free survival (DFS) (85.4% vs. 71.6%, p=0.005), and overall survival (OS) (93.5%vs. 83.5%, p=0.010). In multivariate analysis, goserelin treatment was an independentfactor influencing DMFS (hazard ratio [HR], 1.603; 95% confidence interval [CI], 1.228 to2.092; p=0.001), DFS (HR, 1.606; 95% CI, 1.231 to 2.096; p=0.001), and OS (HR, 3.311;95% CI, 1.416 to 7.742; p=0.006). In addition, treatment with goserelin resulted in significantlyimproved LRFS (p=0.039), DMFS (p=0.043), DFS (p=0.036), and OS (p=0.010) inpatients aged < 40 years. In patients aged 40 years, goserelin only improved DMFS(p=0.028) and DFS (p=0.027). ConclusionOvarian ablation with goserelin plus TAM resulted in significantly improved therapeuticefficacy in premenopausal patients with stage II/III hormone receptor-positive breast cancerwithout CIA.
San-Gang Wu,Qun-Li Zeng,Juan Zhou,Jia-Yuan Sun,Fengyan Li,Qin Lin,Huan-Xin Lin,Xun-Xing Gaun,Zhen-Yu He 대한암학회 2015 Cancer Research and Treatment Vol.47 No.4
Purpose This study was conducted to investigate the prognostic value of lymph node ratio (LNR) instage II/III breast cancer patients who undergo mastectomy after neoadjuvant chemotherapy. Materials and MethodsClinical and pathological data describing stage II/III breast cancer patients were includedin this retrospective study. The primary outcomes were locoregional recurrence-free survival(LRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overallsurvival (OS). ResultsAmong 277 patients, there were 43 ypN0, 64 ypN1, 89 ypN2, and 81 ypN3 cases. Additionally, there were 43, 57, 92 and 85 cases in the LNR 0, 0.01-0.20, 0.21-0.65, and> 0.65 groups, respectively. The median follow-up was 49.5 months. Univariate analysisshowed that both ypN stage and LNR were prognostic factors of LRFS, DMFS, DFS, and OS(p < 0.05). Multivariate analysis showed that LNR was an independent prognostic factor ofLRFS, DMFS, DFS, and OS (p < 0.05), while ypN stage had no effect on prognosis (p > 0.05). ConclusionThe integrated use of LNR and ypN may be suitable for evaluation the prognosis of stageII/III breast cancer patients who undergo mastectomy after neoadjuvant chemotherapy.
Qiannan Guo,Runyao Wen,Bin Shao,Yudong Li,Xin Jin,Heran Deng,Jiannan Wu,Fengxi Su,Fengyan Yu 한국유방암학회 2018 Journal of breast cancer Vol.21 No.2
Purpose: The long non-coding RNA H19, a conservatively imprinted gene, acts as a molecular sponge for the let-7 family, which has been identified as a set of tumor suppressors. However, the combined prognostic value of H19 and let-7a signature in breast cancer patients remains unclear. Methods: In this research we assessed the prognostic value of the combined H19 and let-7a signature in breast cancer patients by retrospectively reviewing that data of 79 patients who underwent neoadjuvant chemotherapy; we also investigated the expression and function of H19 in breast cancer cell lines in vitro. Survival data were calculated using the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate survival analyses were conducted using the Cox proportional hazards regression method. As determined using X-tile, the optimal cutoff value for the risk score to assess progression-free survival (PFS) based on the combined signature was –0.1. Results: Patients with an overall positive treatment response had higher let-7a and lower H19 levels. In addition, let-7a expression was negatively correlated with H19 expression. Patients with a risk score of >–0.1 had shorter overall survival and PFS. In vitro data showed that chemoresistant cell lines exhibit higher H19 and lower let-7a levels and knockdown H19 restores paclitaxel sensitivity. Conclusion: Our results suggest that the combined let-7a and H19 signature is a novel prognostic factor for breast cancer patients treated with neoadjuvant chemotherapy.